Cryo-Cell International

Cryo-Cell Announces Plans to Explore Strategic Alternatives and Spin-off Celle Corp. to Maximize Shareholder Value

Retrieved on: 
Monday, March 25, 2024
Genetics, Health, Stem Cells, Other Health, Duke University, Patent, CCEL, Security (finance), Sale, Cryo-Cell International

There is no assurance that such a transaction will take place.

Key Points: 
  • There is no assurance that such a transaction will take place.
  • Celle Corp. was created to hold certain assets of Cryo-Cell not directly associated with the recurring revenue stream from privately banked, umbilical cord blood specimens.
  • The Patent and Technology License Agreement with Duke University has been transferred to Celle Corp. and other assets and liabilities are expected to be transferred in the near future.
  • Further details, once finalized, will be shared in public filings with the Securities and Exchange Commission.

Global Cord Blood & Tissue Banking Industry Market Size, Segmentation & Forecast Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Biotechnology, Catalent, Transplant, Cell, Patient, UCB, LifeCell International, Microsoft Exchange Server, Organization, Regenerative medicine, Cryo-Cell International, Spectrum, Disorder, Umbilical cord, Population growth, Stemcell Technologies, Certification, HSCT, NIH, GMP, Cord blood, The Cooper Companies, Safety, Hematopoietic stem cell transplantation, Artivion, DSM-IV codes, Tissue, Research, Acquisition, Cancer, Leukemia, CBR, Cryopreservation, Cerebral palsy, FDA, CBUS, Sickle cell disease, ClinicalTrials.gov, Registry, Amniotic fluid, Hearing loss, GCBC, MNC, Geography

The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cord Blood & Tissue Banking Industry Report - Market Size, Segmentation, & Forecasts, 2024" report has been added to ResearchAndMarkets.com's offering.
  • There are now over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The report presents findings on the following topics:
    Rate per cord blood unit in the U.S. and Europe
    Number of clinical trials, number of published scientific papers, and amount of NIH funding for cord blood research
    Number and types of patents for cord blood, cord tissue, and placental products
    The report presents a comprehensive analysis of the global cord blood and tissue banking market.

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2023

Retrieved on: 
Wednesday, February 28, 2024
Biotechnology, Health, Science, Stem Cells, Research, CCEL, Cryo-Cell International

Consolidated revenues for fiscal 2023 were $31.3 million compared to $30.3 million for fiscal 2022.

Key Points: 
  • Consolidated revenues for fiscal 2023 were $31.3 million compared to $30.3 million for fiscal 2022.
  • As of the twelve months ended November 30, 2023, revenue increased 3%, costs of sales decreased 4% and selling, general and administrative expenses increased 10%.
  • These losses were offset by a tax benefit in the amount of $3.8 million for the twelve months ended November 30, 2023.
  • David Portnoy, Chairman of the Board and Co-CEO, commented, “In spite of the large non-cash charges, Cryo-Cell had another solid year in fiscal 2023.

Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now Controlled by the World's 10 Largest Cord Blood Banking Operators - ResearchAndMarkets.com

Retrieved on: 
Monday, January 22, 2024
Health, Other Health, GCBC, Catalent, Stemcell Technologies, HSCT, Population growth, Cryopreservation, CBUS, Leukemia, Regenerative medicine, Cord blood, The Cooper Companies, Cerebral palsy, Spectrum, Research, Geography, UCB, LifeCell International, Registry, Hearing loss, Tissue, Cryo-Cell International, Cancer, GMP, ClinicalTrials.gov, Disorder, Acquisition, Sickle cell disease, Safety, Patient, MNC, NIH, Transplant, Certification, FDA, Amniotic fluid, Microsoft Exchange Server, Hematopoietic stem cell transplantation, Cell

There are over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.

Key Points: 
  • There are over 800,000 cord blood units stored in public cord blood banks and more than 6.75 million cord blood and tissue units stored within private banks worldwide.
  • Today, nearly all U.S. cord blood banks and approximately one-third of global cord blood banks offer cord tissue storage.
  • The vast majority of the global cord blood market is now controlled by the world's 10 largest cord blood banking operators.
  • It reveals the identities of companies offering cord blood storage, cord blood processing technologies, cord blood expansion technologies, and cord blood therapeutics on a global basis.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, October 12, 2023
Biotechnology, Health, Science, Stem Cells, Research, Investment, CCEL, Engineering, Risk, Duke, Hypoxia (medical), Medium term note, R, NYSE American, Cerebral palsy, CP, Cryo-Cell International, SWAP, Spectrum, Trial of the century, Pharmaceutical industry

Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023.

Key Points: 
  • Cryo-Cell International, Inc. (NYSE American LLC Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2023.
  • Consolidated revenues for the third quarter of fiscal 2023 were $7.87 million compared to $7.68 million for the third quarter of fiscal 2022.
  • The revenues for the third quarter of fiscal 2023 consisted of $7.86 million in processing and storage fees, $3,000 in product revenue and $4,000 in public banking revenue compared to $7.52 million in processing and storage fees, $21,000 in product revenue and $138,000 in public banking revenue for the third quarter of fiscal 2022.
  • During the three months ended August 31, 2023, revenue increased 2%, cost of sales decreased 8% and selling, general and administration expenses increased 6%.

Global Cryopreservation Bags Market 2023 to 2035: Fueled by Advancements in Biopharmaceutical Industry - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 6, 2023
Health, Pharmaceutical, Tissue, DNA, Cryo-Cell International, Drug development, ATMP, FEP, Research, Cell, Type, Cryopreservation, Regenerative medicine, EVA, Polytetrafluoroethylene, Traction, Freezing, Patient safety, PTFE, Blood, Stem cell, BIOMED, Polyvinyl chloride, Longevity, Gene, Sartorius, PVC, Tea, Fine chemical, Medical device, Thermoplastic, Entegris, Growth

The global cryopreservation bags and freezing bags market is on the brink of a remarkable upswing, poised to achieve a compounded annual growth rate (CAGR) of 8% over the forecast period.

Key Points: 
  • The global cryopreservation bags and freezing bags market is on the brink of a remarkable upswing, poised to achieve a compounded annual growth rate (CAGR) of 8% over the forecast period.
  • The meticulously compiled report titled "The Cryopreservation Bags and Freezing Bags Market: Distribution by Type of Analyte Stored and Key Geographical Regions" provides a panoramic vista into the impending landscape of cryopreservation bags and freezing bags.
  • These entities have made significant strides in the realm of cryopreservation bags and freezing bags, thereby shaping the market landscape.
  • The cryopreservation bags and freezing bags market stands as a testament to innovation, poised to redefine the future of biological storage.

Cord Blood Banking Leader Cryo-Cell Reports Fiscal Second Quarter 2023 Financial Results

Retrieved on: 
Friday, July 14, 2023
Health, Stem Cells, Other Health, Other Science, Research, Science, Biotechnology, CCEL, NYSE American, Trial of the century, Cryo-Cell International, Medium term note, SWAP, Risk, Duke, Engineering

Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023.

Key Points: 
  • Cryo-Cell International, Inc. (NYSE American LLC: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal second quarter ended May 31, 2023.
  • Consolidated revenues for the second quarter of fiscal 2023 were $7.77 million compared to $7.63 million for the second quarter of fiscal 2022, a 2% increase.
  • The revenues for the second quarter of fiscal 2023 consisted of $7.58 million in processing and storage fee revenue, $164,000 in public banking revenue and $27,000 in product revenue compared to $7.48 million in processing and storage fee revenue, $117,000 in public banking revenue and $36,000 in product revenue for the second quarter of fiscal 2022.
  • During the second quarter of fiscal 2023, the Company entered into an interest rate SWAP agreement to manage exposure to interest rate risk related to its variable debt obligation under its Term Note (as previously disclosed).

Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2023 Financial Results

Retrieved on: 
Friday, April 21, 2023
General Health, Health, Stem Cells, Other Health, CCEL, NYSE American, Cryo-Cell International, Acquisition, Sale

Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2023.

Key Points: 
  • Cryo-Cell International, Inc. (NYSE American LLC: CCEL ) (the “Company”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal first quarter ended February 28, 2023.
  • The revenues for the first quarter of fiscal 2023 were $7.82 million compared to $7.26 million for the first quarter of fiscal 2022.
  • The revenues for the first quarter of fiscal 2023 consisted of $7.56 million in processing and storage fee revenue, $32,000 in product revenue and approximately $231,000 in public banking revenue compared to $7.16 million in processing and storage fees, approximately $18,000 in product revenue and approximately $83,000 in public banking revenue for the first quarter of fiscal 2022.
  • The contingent consideration is the current valuation of the potential earnout that Cord:Use Cord Blood Bank, Inc. is entitled to from the Company’s sale of the public cord blood inventory from and after closing of the acquisition of substantially all of Cord:Use’s assets.

Cryo-Cell Reports Financial Results for Fiscal Year Ended November 30, 2022

Retrieved on: 
Tuesday, February 28, 2023
NYSE American, CCEL, Cryo-Cell International, Cryptocurrency

Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021.

Key Points: 
  • Consolidated revenues for fiscal 2022 were $30.3 million compared to $28.9 million for fiscal 2021.
  • The Company reported net income of $2.8 million in fiscal 2022 or $0.33 per basic and diluted share, compared to net income of $2.1 million in fiscal 2021 or $0.26 per basic and $0.25 per diluted shares.
  • Net income for the fiscal year ended November 30, 2022 was due to a 5% increase in revenue, a 2% decrease in cost of sales and a 7% increase in selling, general and administrative expenses compared to the prior fiscal year.
  • Also included in net income for the twelve months ended November 30, 2021 was a public bank inventory impairment charge of $1.2 million.

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023

Retrieved on: 
Thursday, February 9, 2023
Mouse, Research, GAAP, Safety, Urinary tract infection, SAB, COVID-19, VCAP, Pneumonia, Pulmonary hypertension, Hospital, American College of Chest Physicians, NTM, Society, Conference call, Society for Immunotherapy of Cancer, Survival, Immunotherapy, Calendar, PH, Patient, UNO, Patent, Partnership, Delivery, Neoplasm, FDA, Nitric oxide, NO, Metastasis, Fiscal year, COPD, Cryo-Cell International, Investment, CCI, SITC, Stanford University, Pharmaceutical industry, Vaccine, Conference

GARDEN CITY, N.Y., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today announced financial results for its third fiscal quarter ended December 31, 2022.

Key Points: 
  • “We are successfully executing on our planned limited launch of LungFit PH in the United States.
  • General and administrative expenses for the fiscal quarter ended December 31, 2022 increased to $8.9 million, compared with $4.9 million for the fiscal quarter ended December 31, 2021.
  • As of December 31, 2022, the Company reported cash and cash equivalents, marketable securities, and restricted cash of $63.2 million.
  • Through the first nine months of the Company’s fiscal year 2023, total cash burn was $27.0 million which includes $2.5 million in non-recurring expense.